Summary: The MeCP2 gene regulates key molecular and synaptic mechanisms that shape ketamine’s long-term antidepressant effects, enhancing synaptic strength and plasticity and contributing to cumulative behavioral benefits over time.
Source: Vanderbilt University
New research from Professor Lisa Monteggia and colleagues builds on recent findings about ketamine’s rapid antidepressant action to demonstrate how the MeCP2 gene and associated changes in synaptic plasticity are essential for maintaining the drug’s longer-term antidepressant effects.
Previous work had already implicated MeCP2 in responses to conventional antidepressants. Monteggia and her team show that MeCP2 also cooperates with ketamine’s initial molecular targets to sustain antidepressant benefit beyond the immediate response. In particular, phosphorylation of MeCP2 at Ser421 (pMeCP2) appears to be a necessary step for the prolonged, but not the immediate, behavioral effects of rapidly acting antidepressants.
The researchers found that MeCP2 influences both ketamine’s behavioral outcomes and the potentiation of synapses—the process by which synapses become stronger and more effective. This strengthening contributes to improved antidepressant responses over time. Importantly, the study emphasizes that ketamine’s long-term benefits rely on dynamic synaptic adaptability (plasticity), not merely on static structural changes.
Beyond single-dose effects, repeated ketamine exposure produced enhanced synaptic plasticity in the investigators’ experiments. The team described this enhanced capacity for change as “metaplasticity”—an increased plasticity of plasticity—which may underlie why repeated dosing can produce cumulative and extended antidepressant effects.
Why this matters
“We think we have the pathway in the brain to engage these long-term effects,” said Monteggia, director of the Vanderbilt Brain Institute. Identifying the brain processes responsible for sustained antidepressant action is essential to translate basic findings into improved treatments. This study provides a plausible mechanism linking BDNF signaling to MeCP2 phosphorylation and long-term regulation of synaptic strength, offering a major step forward in explaining how ketamine produces sustained antidepressant responses.
A key practical implication of this discovery is the possibility of designing interventions that activate the neural pathway responsible for prolonging ketamine’s antidepressant effect without administering the drug itself. Although ketamine shows considerable promise for treatment-resistant depression and acts rapidly in many patients, it carries risks including potential for abuse and psychomimetic effects. Low clinical doses are generally tolerated, but the long-term consequences of repeated ketamine exposure are not fully understood. Targeting the MeCP2-related pathway could provide a way to harness ketamine’s beneficial mechanisms while reducing reliance on the drug and minimizing unintended side effects.
What’s next
Because MeCP2 can regulate gene expression, the research team is now focused on mapping the broader neural pathway that links BDNF signaling to pMeCP2 and synaptic plasticity. They are also investigating whether shared mechanisms exist between ketamine and traditional antidepressants that could be leveraged to extend treatment durability for a wider range of therapies.
Funding
This research was supported by National Institutes of Health grants MH070727, MH081060, and MH066198; the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (grant 2016R1A6A3A03008533); and the Swedish Pharmaceutical Society and the Swedish Society for Medical Research.
About this ketamine and depression research news
Source: Vanderbilt University
Contact: Marissa Shapiro – Vanderbilt University
Image: The image is in the public domain
Original Research: Closed access. “Sustained effects of rapidly acting antidepressants require BDNF-dependent MeCP2 phosphorylation” by Ji-Woon Kim, Anita E. Autry, Elisa S. Na, Megumi Adachi, Carl Björkholm, Ege T. Kavalali & Lisa M. Monteggia. Nature Neuroscience
Abstract
Sustained effects of rapidly acting antidepressants require BDNF-dependent MeCP2 phosphorylation
Rapidly acting antidepressants such as ketamine and scopolamine can produce behavioral improvements that last from several days to more than a week for some patients. However, the molecular mechanisms that maintain these antidepressant effects over time have been unclear. The study demonstrates that phosphorylation of methyl-CpG-binding protein 2 (MeCP2) at Ser421 (pMeCP2) is essential for sustained—but not immediate—antidepressant action of ketamine and scopolamine in mice.
The results position pMeCP2 downstream of brain-derived neurotrophic factor (BDNF), a key mediator of rapid antidepressant effects, and show that pMeCP2 is necessary for long-term regulation of synaptic strength following treatment. Together, these findings identify pMeCP2 and the associated synaptic plasticity processes as critical determinants of sustained antidepressant efficacy.